The other face of depression, reduced positive affect: The role of catecholamines in causation and cure

David Nutt, Koen Demyttenaere, Z. Janka, Trond Aarre, Michel Bourin, Pier Luigi Canonico, Jose Luis Carrasco, Steven Stahl

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

Despite significant advances in pharmacologic therapy of depression over the past two decades, a substantiaL proportion of patients faiL to respond or experience onLy partiaL response to serotonin re-uptake inhibitor antidepressants, resuLting in chronic functionaL impairment. There appears to be a pattern of symptoms that are inadequateLy addressed by serotonergic antidepressants - Loss of pLeasure, Loss of interest, fatigue and Loss of energy. These symptoms are key to the maintenance of drive and motivation. ALthough these symptoms are variousLy defined, they are consistent with the concept of 'decreased positive affect'. Positive affect subsumes a broad range of positive mood states, incLuding feeLings of happiness (joy), interest, energy, enthusiasm, aLertness and seLfconfidence. ALthough preLiminary, there is evidence to suggest that antidepressants that enhance noradrenergic and dopaminergic activity may afford a therapeutic advantage over serotonergic antidepressants in the treatment of symptoms associated with a reduction in positive affect. Dopaminergic and noradrenergic agents, incLuding the duaL acting norepinephrine and dopamine re-uptake inhibitors, have demonstrated antidepressant activity in the absence of serotonergic function, showing simiLar efficacy to both tricycLic and serotonin re-uptake inhibitor antidepressants. Moreover, the norepinephrine and dopamine re-uptake inhibitor bupropion has been shown to significantLy improve symptoms of energy, pLeasure and interest in patients with depression with predominant baseLine symptoms of decreased pLeasure, interest and energy. Focusing treatment on the predominant or driving symptomatoLogy for an individuaL patient with major depression couLd potentially improve rates of response and remission.

Original languageEnglish
Pages (from-to)461-471
Number of pages11
JournalJournal of Psychopharmacology
Volume21
Issue number5
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Causality
Antidepressive Agents
Catecholamines
Depression
Pleasure
Dopamine Uptake Inhibitors
Serotonin Uptake Inhibitors
Norepinephrine
Bupropion
Dopamine Agents
Happiness
Therapeutics
Fatigue
Motivation
Emotions
Maintenance

Keywords

  • Bupropion
  • Catecholamines
  • Dopamine
  • MeSH (max 10): major depressive disorder
  • Norepinephrine
  • Positive affect

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

The other face of depression, reduced positive affect : The role of catecholamines in causation and cure. / Nutt, David; Demyttenaere, Koen; Janka, Z.; Aarre, Trond; Bourin, Michel; Canonico, Pier Luigi; Carrasco, Jose Luis; Stahl, Steven.

In: Journal of Psychopharmacology, Vol. 21, No. 5, 09.2007, p. 461-471.

Research output: Contribution to journalArticle

Nutt, D, Demyttenaere, K, Janka, Z, Aarre, T, Bourin, M, Canonico, PL, Carrasco, JL & Stahl, S 2007, 'The other face of depression, reduced positive affect: The role of catecholamines in causation and cure', Journal of Psychopharmacology, vol. 21, no. 5, pp. 461-471. https://doi.org/10.1177/0269881106069938
Nutt, David ; Demyttenaere, Koen ; Janka, Z. ; Aarre, Trond ; Bourin, Michel ; Canonico, Pier Luigi ; Carrasco, Jose Luis ; Stahl, Steven. / The other face of depression, reduced positive affect : The role of catecholamines in causation and cure. In: Journal of Psychopharmacology. 2007 ; Vol. 21, No. 5. pp. 461-471.
@article{fc0ec1d8cc724ecab085372cc78c5afe,
title = "The other face of depression, reduced positive affect: The role of catecholamines in causation and cure",
abstract = "Despite significant advances in pharmacologic therapy of depression over the past two decades, a substantiaL proportion of patients faiL to respond or experience onLy partiaL response to serotonin re-uptake inhibitor antidepressants, resuLting in chronic functionaL impairment. There appears to be a pattern of symptoms that are inadequateLy addressed by serotonergic antidepressants - Loss of pLeasure, Loss of interest, fatigue and Loss of energy. These symptoms are key to the maintenance of drive and motivation. ALthough these symptoms are variousLy defined, they are consistent with the concept of 'decreased positive affect'. Positive affect subsumes a broad range of positive mood states, incLuding feeLings of happiness (joy), interest, energy, enthusiasm, aLertness and seLfconfidence. ALthough preLiminary, there is evidence to suggest that antidepressants that enhance noradrenergic and dopaminergic activity may afford a therapeutic advantage over serotonergic antidepressants in the treatment of symptoms associated with a reduction in positive affect. Dopaminergic and noradrenergic agents, incLuding the duaL acting norepinephrine and dopamine re-uptake inhibitors, have demonstrated antidepressant activity in the absence of serotonergic function, showing simiLar efficacy to both tricycLic and serotonin re-uptake inhibitor antidepressants. Moreover, the norepinephrine and dopamine re-uptake inhibitor bupropion has been shown to significantLy improve symptoms of energy, pLeasure and interest in patients with depression with predominant baseLine symptoms of decreased pLeasure, interest and energy. Focusing treatment on the predominant or driving symptomatoLogy for an individuaL patient with major depression couLd potentially improve rates of response and remission.",
keywords = "Bupropion, Catecholamines, Dopamine, MeSH (max 10): major depressive disorder, Norepinephrine, Positive affect",
author = "David Nutt and Koen Demyttenaere and Z. Janka and Trond Aarre and Michel Bourin and Canonico, {Pier Luigi} and Carrasco, {Jose Luis} and Steven Stahl",
year = "2007",
month = "9",
doi = "10.1177/0269881106069938",
language = "English",
volume = "21",
pages = "461--471",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - The other face of depression, reduced positive affect

T2 - The role of catecholamines in causation and cure

AU - Nutt, David

AU - Demyttenaere, Koen

AU - Janka, Z.

AU - Aarre, Trond

AU - Bourin, Michel

AU - Canonico, Pier Luigi

AU - Carrasco, Jose Luis

AU - Stahl, Steven

PY - 2007/9

Y1 - 2007/9

N2 - Despite significant advances in pharmacologic therapy of depression over the past two decades, a substantiaL proportion of patients faiL to respond or experience onLy partiaL response to serotonin re-uptake inhibitor antidepressants, resuLting in chronic functionaL impairment. There appears to be a pattern of symptoms that are inadequateLy addressed by serotonergic antidepressants - Loss of pLeasure, Loss of interest, fatigue and Loss of energy. These symptoms are key to the maintenance of drive and motivation. ALthough these symptoms are variousLy defined, they are consistent with the concept of 'decreased positive affect'. Positive affect subsumes a broad range of positive mood states, incLuding feeLings of happiness (joy), interest, energy, enthusiasm, aLertness and seLfconfidence. ALthough preLiminary, there is evidence to suggest that antidepressants that enhance noradrenergic and dopaminergic activity may afford a therapeutic advantage over serotonergic antidepressants in the treatment of symptoms associated with a reduction in positive affect. Dopaminergic and noradrenergic agents, incLuding the duaL acting norepinephrine and dopamine re-uptake inhibitors, have demonstrated antidepressant activity in the absence of serotonergic function, showing simiLar efficacy to both tricycLic and serotonin re-uptake inhibitor antidepressants. Moreover, the norepinephrine and dopamine re-uptake inhibitor bupropion has been shown to significantLy improve symptoms of energy, pLeasure and interest in patients with depression with predominant baseLine symptoms of decreased pLeasure, interest and energy. Focusing treatment on the predominant or driving symptomatoLogy for an individuaL patient with major depression couLd potentially improve rates of response and remission.

AB - Despite significant advances in pharmacologic therapy of depression over the past two decades, a substantiaL proportion of patients faiL to respond or experience onLy partiaL response to serotonin re-uptake inhibitor antidepressants, resuLting in chronic functionaL impairment. There appears to be a pattern of symptoms that are inadequateLy addressed by serotonergic antidepressants - Loss of pLeasure, Loss of interest, fatigue and Loss of energy. These symptoms are key to the maintenance of drive and motivation. ALthough these symptoms are variousLy defined, they are consistent with the concept of 'decreased positive affect'. Positive affect subsumes a broad range of positive mood states, incLuding feeLings of happiness (joy), interest, energy, enthusiasm, aLertness and seLfconfidence. ALthough preLiminary, there is evidence to suggest that antidepressants that enhance noradrenergic and dopaminergic activity may afford a therapeutic advantage over serotonergic antidepressants in the treatment of symptoms associated with a reduction in positive affect. Dopaminergic and noradrenergic agents, incLuding the duaL acting norepinephrine and dopamine re-uptake inhibitors, have demonstrated antidepressant activity in the absence of serotonergic function, showing simiLar efficacy to both tricycLic and serotonin re-uptake inhibitor antidepressants. Moreover, the norepinephrine and dopamine re-uptake inhibitor bupropion has been shown to significantLy improve symptoms of energy, pLeasure and interest in patients with depression with predominant baseLine symptoms of decreased pLeasure, interest and energy. Focusing treatment on the predominant or driving symptomatoLogy for an individuaL patient with major depression couLd potentially improve rates of response and remission.

KW - Bupropion

KW - Catecholamines

KW - Dopamine

KW - MeSH (max 10): major depressive disorder

KW - Norepinephrine

KW - Positive affect

UR - http://www.scopus.com/inward/record.url?scp=34547093178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547093178&partnerID=8YFLogxK

U2 - 10.1177/0269881106069938

DO - 10.1177/0269881106069938

M3 - Article

C2 - 17050654

AN - SCOPUS:34547093178

VL - 21

SP - 461

EP - 471

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 5

ER -